CarcinoTest™ – Circulating Tumor Cell Test

CarcinoTest™ is an advanced blood-based test designed to detect and evaluate Circulating Tumor Cells, also known as CTCs.

CTCs are cancer-related cells that may break away from a tumour and enter the bloodstream. Their presence may provide important information about cancer activity, possible spread, treatment response, and ongoing monitoring needs.

Unlike conventional screening methods that rely mainly on imaging or tumour markers, CarcinoTest™ provides a deeper biological view by studying cancer-related cells circulating in the blood.

This makes CarcinoTest™ a valuable tool for doctor-led cancer monitoring, early investigation support, and personalised oncology planning.

WHAT CARCINOTEST™ IS?

CarcinoTest™ is a Circulating Tumor Cell Test performed using a blood sample.

Circulating Tumor Cells, or CTCs, are cells that may detach from a tumour and travel through the bloodstream. These cells are clinically important because they may be associated with cancer progression, recurrence risk, and metastatic potential.

This test may help doctors better understand whether cancer-related cells are present in circulation and whether further monitoring, investigation, or treatment-response review may be needed.

WHY CIRCULATING TUMOR CELLS MATTER?

Cancer cells may not always remain confined to the original tumour site.

Some cells may enter the bloodstream and travel to other parts of the body. These circulating cells may act as early indicators of possible disease activity or microscopic spread.

Detecting and monitoring CTCs may help provide useful insight into:

• Cancer-Cell Activity: Helps evaluate whether cancer-related cells are circulating in the bloodstream.
• Micro-Metastatic Risk: May support early understanding of possible microscopic spread risk.
• Treatment Response: Can be used to compare changes before, during, or after cancer treatment.
• Post-Surgery Monitoring: May help doctors monitor patients after surgery for additional biological insight.
• Personalised Oncology Planning: Provides additional information that may support doctor-led decision-making.

HOW CARCINOTEST™ WORKS?

The process begins with a professional blood collection.

The blood sample is then analysed to identify and evaluate circulating tumour cells. The result may provide information about the presence, quantity, and biological characteristics of cancer-related cells in the bloodstream.

The general process includes:

• Consultation: The patient’s medical history, cancer risk, symptoms, previous results, or current treatment status are reviewed.
• Blood Collection: A blood sample is collected by trained healthcare personnel.
• Laboratory Analysis: The sample is analysed to detect and evaluate circulating tumour cells.
• Report Generation: A report is prepared for doctor-led interpretation.
• Professional Review: The result is reviewed together with the patient’s clinical condition, imaging, tumour markers, treatment history, and other relevant findings.

WHAT MAKES CARCINOTEST™ DIFFERENT?

• Blood-Based Cancer Monitoring
  • CarcinoTest™ uses a blood sample to study circulating tumour cells, offering an additional layer of information beyond conventional tumour markers.
• Minimally Invasive
  • The test requires only a blood draw, without radiation exposure.
• Supports Repeated Monitoring
  • Because it is blood-based, CarcinoTest™ may be repeated over time to monitor changes.
• Provides Cellular-Level Insight
  • Instead of only looking at tumour size, CarcinoTest™ helps evaluate cancer-related cellular activity in circulation.
• Supports Treatment Response Review
  • Changes in CTC levels or characteristics may help doctors assess how the patient is responding to treatment.
• Supports Personalised Oncology Planning
  • The result may help guide further investigation, monitoring frequency, or treatment-planning discussions.

KEY BENEFITS

• Detects Circulating Tumor Cells
  • Helps identify cancer-related cells that may be present in the bloodstream.
• Supports Early Investigation
  • May provide early biological insight when further cancer-related evaluation is needed.
• Helps Monitor Treatment Response
  • Can be used before, during, or after treatment to support response tracking.
• Supports Post-Surgery Monitoring
  • May help provide additional insight after tumour removal or cancer-related surgery.
• Goes Beyond Routine Tumour Markers
  • Provides cellular-level information that may complement conventional blood tests and imaging.
• Useful for Ongoing Cancer Management
  • Supports doctor-led monitoring in patients undergoing chemotherapy, immunotherapy, targeted therapy, integrative oncology support, or follow-up care.

WHO CARCINOTEST™ IS DESIGNED FOR?

CarcinoTest™ may be considered for individuals who require deeper cancer-related monitoring or investigation support.

It may be suitable for individuals who:

• have a personal history of cancer
• have a family history of cancer
• have elevated or borderline tumour markers
• are undergoing cancer treatment
• want to assess treatment response
• have completed cancer surgery and require monitoring
• have abnormal screening results requiring further investigation
• have risk factors such as long-term smoking or chronic hepatitis B/C
• have positive stool occult blood test
• have abnormal mammogram findings
• have abnormal Pap smear / cervical screening findings
• are advised by a doctor to undergo further cancer-related evaluation

CarcinoTest™ should always be interpreted by qualified healthcare professionals.

WHEN CARCINOTEST™ MAY BE RECOMMENDED?

CarcinoTest™ may be considered:

• before starting a cancer treatment plan
• during active cancer treatment
• after chemotherapy, immunotherapy, targeted therapy, or surgery
• during post-treatment follow-up
• when tumour markers are elevated or unclear
• when imaging results need additional biological context
• when there is concern about recurrence or microscopic spread
• when doctors require deeper cancer-cell activity information

WHAT THE RESULT MAY SHOW?

CarcinoTest™ may provide information related to:

• presence of circulating tumour cells
• CTC count or level
• cancer-cell activity in circulation
• possible metastatic potential
• treatment-response trend
• post-surgery monitoring insight
• need for further investigation or closer follow-up

A concerning result does not automatically confirm cancer progression. It must be reviewed together with imaging, tumour markers, symptoms, medical history, and doctor assessment.

IMPORTANT NOTICE

CarcinoTest™ is a professional cancer monitoring and investigation-support test. It is not intended to independently diagnose cancer, treat cancer, cure cancer, or prevent cancer.

Results must be interpreted by qualified medical professionals and reviewed together with the patient’s symptoms, medical history, imaging, tumour markers, laboratory findings, treatment status, and overall clinical condition.

Further medical investigation may be required depending on the result and clinical context.